Common Variants for Cardiovascular Disease: Clinical Utility Confirmed.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Genetic Polymorphism ofBiomolecules · 2025
   Article
2. Genome-wide association study of therapeutic response to statin drugs in cardiovascular disease.Scientific reports · 2024
   Article
3. eQTLs as causal instruments for the reconstruction of hormone linked gene networks.Frontiers in endocrinology · 2022
   Review
4. Vitamin D Receptor Gene Polymorphism and Vitamin D Status in Population of Patients with Cardiovascular Disease-A Preliminary Study.Nutrients · 2021
   Article
5. Human muscle-specific A-kinase anchoring protein polymorphisms modulate the susceptibility to cardiovascular diseases by altering cAMP/PKA signaling.American journal of physiology. Heart and circulatory physiology · 2018
   Article

Corrections and comments

• Comment on
  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.2017

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as